Bizarre Patents
A helium-filled sun shade for protecting individuals engaged in outdoor activities.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120045438 | ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.... | 02/23/2012 |
| 20110318345 | NASAL DELIVERY substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nas... | 12/29/2011 |
| 20110280832 | EOTAXIN-2 (CCL24) INHIBITORS IN INFLAMMATORY, AUTOIMMUNE, AND CARDIOVASCULAR DISORDERS The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune enceph... | 11/17/2011 |
| 20110262449 | METHOD FOR THE TREATMENT OF GOUT OR PSEUDOGOUT The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.... | 10/27/2011 |
| 20110256132 | MYOSTATIN BINDING PROTEINS Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. Furthermore, description of the... | 10/20/2011 |
| 20110250210 | Neutralizing Antibodies and Fragments Thereof Directed Against Platelet Factor-4 Variant 1 (PF4V1) The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.... | 10/13/2011 |
| 20110243936 | TNFalpha-NEUTRALIZING ANTIBODIES The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal... | 10/06/2011 |
| 20110223178 | Antibodies That Specifically Bind to Chemokine Beta-4 The present invention relates to antibodies and related molecules that specifically bind to CK-β4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune sys... | 09/15/2011 |
| 20110206663 | Anti-Interferon-Alpha Antibodies The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnos... | 08/25/2011 |
| 20110189082 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-ind... | 08/04/2011 |
| 20110182904 | ANTIBODIES TO BONE MORPHOGENIC PROTEINS AND RECEPTORS THEREFOR AND METHODS FOR THEIR USE The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expre... | 07/28/2011 |
| 20110182906 | FULLY HUMAN ANTIBODY TO HUMAN TNF-ALPHA, MOLECULAR EVOLUTION AND USE THEREOF The present invention relates to the discovery and improvement of proteins that can specifically bind with human TNFa (Tumor Necrosis Factor alpha), the proteins are full human anti human TNFa monoclonal antibodies derived from human B cells. This invention disclosed th... | 07/28/2011 |
| 20110182905 | MONOCLONAL ANTIBODIES THAT BIND TO HGM-CSF AND MEDICAL COMPOSITIONS COMPRISING SAME Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The ... | 07/28/2011 |
| 20110182892 | Methods to identify responsive patients The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab.... | 07/28/2011 |
| 20110165063 | IL-1 BINDING PROTEINS The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be... | 07/07/2011 |
| 20110150895 | ANTIBODY SPECIFICALLY BINDING TO ANGIOPOIETIN-2 AND USE THEREOF An antibody specifically binding to angiopoietin-2, and antigen-binding fragments thereof, and a use thereof are disclosed.... | 06/23/2011 |
| 20110142846 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the level... | 06/16/2011 |
| 20110142761 | IL-1 BINDING PROTEINS The present invention describes IL-1β binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1β. Binding proteins of the invention have high affinity for IL-1β and neutralize IL-1β activity. A binding protein of the invention can be... | 06/16/2011 |
| 20110135597 | Uses of Mammalian Cytokine; Related Reagents Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.... | 06/09/2011 |
| 20110136172 | MAMMALIAN CYTOKINES; RELATED REAGENTS Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provid... | 06/09/2011 |
| 20110130548 | ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 anti... | 06/02/2011 |
| 20110091968 | MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a metho... | 04/21/2011 |
| 20110059107 | ANTIKINE ANTIBODIES THAT BIND TO MULTIPLE CC CHEMOKINES An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producin... | 03/10/2011 |
| 20110052596 | ANTIBODIES TO IL-17A Engineered antibodies to human IL-17A are provided, as well as uses thereof.... | 03/03/2011 |
| 20110053221 | RECOMBINANT PRODUCTION OF AUTHENTIC HUMAN PROTEINS USING HUMAN CELL EXPRESSION SYSTEMS The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against th... | 03/03/2011 |
| 20110044996 | NEUTRALIZING ANTIBODIES The present invention provides antibodies that bind, interact or otherwise associate with GM-CSF or a fragment, portion or part thereof and antagonize or neutralize GM-CSF activity. In accordance with embodiments of the present invention humanized monoclonal antibodies ... | 02/24/2011 |
| 20110034383 | CXCL12 GAMMA A CHEMOKINE AND USES THEREOF Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans.... | 02/10/2011 |
| 20110002941 | Antibodies that Specifically Bind Hedgehog-Derived Polypeptides The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain... | 01/06/2011 |
| 20100316634 | RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.... | 12/16/2010 |
| 20100297110 | ANTIBODY SPECIFIC FOR HUMAN IL-4 FOR THE TREATMENT OF CANCER The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.... | 11/25/2010 |
| 20100291088 | IL-18 BINDING PROTEINS The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or tha... | 11/18/2010 |
| 20100285036 | Anti-CD100 Neutralizing Antibodies and Methods of Using the Same Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.... | 11/11/2010 |
| 20100266613 | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES The present invention relates to antibodies directed to the tumor necrosis factor alpha (“TNF-α”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of TNF-α.... | 10/21/2010 |
| 20100266531 | IL-17 BINDING PROTEINS Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.... | 10/21/2010 |
| 20100260775 | Treatment Of Interstitial Cystitis The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.... | 10/14/2010 |
| 20100260767 | Composition and Method for Treating Inflammatory Disorders Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.... | 10/14/2010 |
| 20100247545 | ANTIBODIES TO M-CSF The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions there... | 09/30/2010 |
| 20100247431 | POLYPEPTIDES INCLUDING MODIFIED CONSTANT REGIONS Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native... | 09/30/2010 |
| 20100239590 | JOINT DESTRUCTION BIOMARKERS FOR ANTI-IL-17A THERAPY OF INFLAMMATORY JOINT DISEASE Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oli... | 09/23/2010 |
| 20100221254 | Methods and Compositions for PDGF-C Activation and Inhibition Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administ... | 09/02/2010 |
